STUDY OBJECTIVES: Idiopathic rapid eye movement (REM) sleep behavior disorder (RBD) is a harbinger of synuclein-mediated neurodegenerative diseases. It is unknown if this also applies to isolated REM sleep without atonia (RWA). We performed a long-term follow-up investigation of subjects with isolated RWA. METHODS: Participants were recruited from 50 subjects with isolated RWA who were identified at the sleep laboratory of the Department of Neurology at the Medical University of Innsbruck between 2003 and 2005. Eligible subjects underwent follow-up clinical examination, polysomnography, and assessment of neurodegenerative biomarkers (cognitive impairment, finger speed deficit, impaired color vision, olfactory dysfunction, orthostatic hypotension, and substantia nigra hyperechogenicity). RESULTS: After a mean of 8.6 ± 0.9 y, 1 of 14 participating subjects (7.3%) progressed to RBD. Ten of 14 RWA subjects (71.4%) were positive for at least one neurodegenerative biomarker. Substantia nigra hyperechogenicity and presence of mild cognitive impairment were both present in 4 of 14 subjects with isolated RWA. Electromyographic activity measures increased significantly from baseline to follow-up polysomnography ("any" mentalis and both anterior tibialis muscles: 32.5 ± 9.4 versus 52.2 ± 16.6%; p = 0.004). CONCLUSION: This study provides first evidence that isolated RWA is an early biomarker of synuclein-mediated neurodegeneration. These results will have to be replicated in larger studies with longer observational periods. If confirmed, these disease findings have implications for defining at-risk cohorts for Parkinson disease.
STUDY OBJECTIVES:Idiopathic rapid eye movement (REM) sleep behavior disorder (RBD) is a harbinger of synuclein-mediated neurodegenerative diseases. It is unknown if this also applies to isolated REM sleep without atonia (RWA). We performed a long-term follow-up investigation of subjects with isolated RWA. METHODS:Participants were recruited from 50 subjects with isolated RWA who were identified at the sleep laboratory of the Department of Neurology at the Medical University of Innsbruck between 2003 and 2005. Eligible subjects underwent follow-up clinical examination, polysomnography, and assessment of neurodegenerative biomarkers (cognitive impairment, finger speed deficit, impaired color vision, olfactory dysfunction, orthostatic hypotension, and substantia nigra hyperechogenicity). RESULTS: After a mean of 8.6 ± 0.9 y, 1 of 14 participating subjects (7.3%) progressed to RBD. Ten of 14 RWA subjects (71.4%) were positive for at least one neurodegenerative biomarker. Substantia nigra hyperechogenicity and presence of mild cognitive impairment were both present in 4 of 14 subjects with isolated RWA. Electromyographic activity measures increased significantly from baseline to follow-up polysomnography ("any" mentalis and both anterior tibialis muscles: 32.5 ± 9.4 versus 52.2 ± 16.6%; p = 0.004). CONCLUSION: This study provides first evidence that isolated RWA is an early biomarker of synuclein-mediated neurodegeneration. These results will have to be replicated in larger studies with longer observational periods. If confirmed, these disease findings have implications for defining at-risk cohorts for Parkinson disease.
Authors: Ronald B Postuma; Isabelle Arnulf; Birgit Hogl; Alex Iranzo; Tomoyuki Miyamoto; Yves Dauvilliers; Wolfgang Oertel; Yo-El Ju; Monica Puligheddu; Poul Jennum; Amelie Pelletier; Christina Wolfson; Smaranda Leu-Semenescu; Birgit Frauscher; Masayuki Miyamoto; Valerie Cochen De Cock; Marcus M Unger; Karin Stiasny-Kolster; Maria Livia Fantini; Jacques Y Montplaisir Journal: Mov Disord Date: 2012-05-30 Impact factor: 10.338
Authors: R B Postuma; J Y Montplaisir; A Pelletier; Y Dauvilliers; W Oertel; A Iranzo; L Ferini-Strambi; I Arnulf; B Hogl; R Manni; T Miyamoto; G Mayer; K Stiasny-Kolster; M Puligheddu; Y Ju; P Jennum; K Sonka; J Santamaria; M L Fantini; M Zucconi; S Leu-Semenescu; B Frauscher; M Terzaghi; M Miyamoto; M M Unger; V Cochen De Cock; C Wolfson Journal: Neurology Date: 2012-06-27 Impact factor: 9.910
Authors: Jacques Montplaisir; Jean-Francois Gagnon; Maria Livia Fantini; Ronald B Postuma; Yves Dauvilliers; Alex Desautels; Sylvie Rompré; Jean Paquet Journal: Mov Disord Date: 2010-10-15 Impact factor: 10.338
Authors: Ronald B Postuma; Jean-François Gagnon; Mélanie Vendette; Catherine Desjardins; Jacques Y Montplaisir Journal: Ann Neurol Date: 2011-01-18 Impact factor: 10.422
Authors: Birgit Frauscher; Laura Ehrmann; Laura Zamarian; Florentine Auer; Thomas Mitterling; David Gabelia; Elisabeth Brandauer; Margarete Delazer; Werner Poewe; Birgit Högl Journal: Mov Disord Date: 2012-11 Impact factor: 10.338
Authors: Stuart J McCarter; Erik K St Louis; David J Sandness; Ethan J Duwell; Paul C Timm; Bradley F Boeve; Michael H Silber Journal: Sleep Med Date: 2016-05-11 Impact factor: 3.492
Authors: Jonathan E Elliott; Ryan A Opel; Dennis Pleshakov; Tara Rachakonda; Alexander Q Chau; Kristianna B Weymann; Miranda M Lim Journal: Sleep Date: 2020-03-12 Impact factor: 5.849
Authors: John C Feemster; Youngsin Jung; Paul C Timm; Sarah M Westerland; Thomas R Gossard; Luke N Teigen; Lauren A Buchal; Elena F D Cattaneo; Charlotte A Imlach; Stuart J Mccarter; Kevin L Smith; Bradley F Boeve; Michael H Silber; Erik K St Louis Journal: Sleep Date: 2019-10-09 Impact factor: 5.849